UniCredit SpA (CRIN)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 71.73 |
|---|---|
| 52-week range | 57.66 – 86.42 |
| Return, 1 month / 3 months | −14.0% / −9.5% |
| Return, 1 year / 3 years | +20.7% / +268.8% |
| Trend | Below its 200-day average |
| RSI (14) | 31 |
| Volatility (1 year) | 30.8% |
| Worst drawdown (1 year) | -24.1% |
| Average daily value traded | 0.38M EUR |
| Dividend yield | 4.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
UniCredit is a banking group based in Milan, Italy, offering retail and commercial banking, corporate and investment banking, and wealth management services. It serves individuals, small businesses, companies and institutional clients, mainly across Italy and other European markets where its subsidiary banks operate under local brands. Its activities include deposits, lending, payments, asset management and capital markets services, and it also runs operations in central and eastern Europe.
The shares are listed on the XETRA Stock Exchange in Germany under the code CRIN, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
UniCredit SpA (CRIN) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 71.73 on 23 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 204 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 20.7% and over the last three months it fell 9.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -3.9% | ||
| From 52-week high | -16.1% | ||
| Momentum | 62 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -9.5% | ||
| 6-month return | 11.3% | ||
| 12-month return, skipping the last month | 40.3% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.1% | ||
| Liquidity | 62 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.38M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 63 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.4% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −6.2% |
|---|---|
| 1 month | −14.0% |
| 3 months | −9.5% |
| 6 months | +11.3% |
| 1 year | +20.7% |
| 3 years | +268.8% |
| 5 years | +709.8% |
Signals
| 50-day / 200-day average | 81.15 / 74.63 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.96 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Apr 2026 | EUR 1.7208 |
| 24 Nov 2025 | EUR 1.4282 |
| 22 Apr 2025 | EUR 1.4764 |
| 18 Nov 2024 | EUR 0.9261 |
| 22 Apr 2024 | EUR 1.8029 |
| 24 Apr 2023 | EUR 0.9872 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.